Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases
NCT07348588Phase 2Active, not recruiting
- Sponsor
- Centro de Pesquisa Rubens Siqueira
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in retinitis pigmentosa (RP) and geographic atrophy (GA), sponsored by Centro de Pesquisa Rubens Siqueira. Primary endpoints: Field Preservation Deviation Index at 6 months, Mean Deviation at 6 months and 1 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
03
Conditions
retinitis pigmentosa (RP)geographic atrophy (GA)
Beyond the preview
Go deeper on NCT07348588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348588.